Twist Bioscience Corp Cash Flow Statement
TWST / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Twist Bioscience Corp used $48M in operating cash flow and negative free cash flow of $76M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$77.7M | -$208.7M | -$204.6M | -$217.9M | -$152.1M | -$139.9M | -$107.7M | -$71.2M | -$59.3M |
| Depreciation & Amortization | $24.9M | $31.4M | $29.3M | $16.5M | $9.8M | $6.7M | $6.1M | $5.7M | $5.0M |
| Operating Cash Flow | -$47.6M | -$64.1M | -$142.5M | -$124.4M | -$112.2M | -$142.3M | -$87.9M | -$66.2M | -$51.3M |
| Capital Expenditures | $28.0M | $5.1M | $27.8M | $101.9M | $27.1M | $9.9M | $14.8M | $3.7M | $6.6M |
| Free Cash Flow | -$75.6M | -$69.2M | -$170.3M | -$226.2M | -$139.3M | -$152.1M | -$102.7M | -$69.9M | -$57.9M |